Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
CM.8.1.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.99NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBF.1.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.343NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.4.17 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.25.1.2 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.409NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.83NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.310NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.362.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.162NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Y.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.86NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.154NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.4.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
A.2.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.41NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.137NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.446NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.76 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.398NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.163NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
P.3 (Theta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.38.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAVNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BE.1.4.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBC.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BM.4.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.20NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.77NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.60NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.9.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.11NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.3.15NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.6.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.1.35NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.45NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.31NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.39.1.2 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.4.15 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.75.10NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.36.21NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.1.23NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.134NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.39.1.3 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BN.1.3.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.38NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBC.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Q.2 (Alpha)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used